Brokers Set Expectations for LVTX Q1 Earnings

LAVA Therapeutics (NASDAQ:LVTX) – Analysts at HC Wainwright issued their Q1 2025 earnings estimates for shares of LAVA Therapeutics in a research note issued on Monday, March 31st. HC Wainwright analyst A. He forecasts that the company will post earnings per share of ($0.40) for the quarter. HC Wainwright currently has a “Neutral” rating and a $1.50 target price on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for LAVA Therapeutics’ FY2025 earnings at ($1.46) EPS, FY2026 earnings at ($0.79) EPS, FY2027 earnings at ($0.40) EPS, FY2028 earnings at ($0.39) EPS and FY2029 earnings at ($0.40) EPS.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.18. The firm had revenue of $2.50 million during the quarter, compared to analyst estimates of $2.40 million.

A number of other brokerages have also recently commented on LVTX. JMP Securities reissued a “market perform” rating and issued a $6.00 price objective on shares of LAVA Therapeutics in a research note on Wednesday, December 11th. Citizens Jmp cut shares of LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, December 11th. Leerink Partners reaffirmed a “market perform” rating and issued a $2.00 target price (down previously from $11.00) on shares of LAVA Therapeutics in a research note on Thursday, December 12th. Finally, Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $3.17.

LAVA Therapeutics Stock Down 7.1 %

Shares of LVTX stock opened at $1.18 on Thursday. The stock has a market cap of $31.03 million, a P/E ratio of -1.15 and a beta of 0.48. LAVA Therapeutics has a fifty-two week low of $0.85 and a fifty-two week high of $3.57. The business has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $1.36.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of LVTX. Virtu Financial LLC purchased a new position in LAVA Therapeutics during the third quarter worth approximately $32,000. BNP Paribas Financial Markets purchased a new position in shares of LAVA Therapeutics in the 4th quarter worth $40,000. Finally, Sanofi purchased a new position in shares of LAVA Therapeutics in the 4th quarter worth $1,825,000.

About LAVA Therapeutics

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.